{"id":"NCT01588353","sponsor":"Asahi Kasei Pharma Corporation","briefTitle":"Collagenase Option for Reduction of Dupuytren's Contracture in Japan","officialTitle":"Phase III Study of AK160 in Patients With Dupuytren's Contracture","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2012-04-30","resultsPosted":"2017-02-14","lastUpdate":"2017-03-21"},"enrollment":104,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Dupuytren's Contracture"],"interventions":[{"type":"DRUG","name":"Collagenase Clostridium Histolyticum","otherNames":["Xiaflex® (US)","Xiapex® (EU)"]}],"arms":[{"label":"AK160 0.58 mg","type":"EXPERIMENTAL"}],"summary":"To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture.\n\nTo determine plasma concentration after the first injection of AK160 in patients with Dupuytren's Contracture.","primaryOutcome":{"measure":"The Percentage of Participants That Were Successfully Treated With a \"Successful Reduction in Contracture to 5°or Less\"","timeFrame":"30 days after the last injection","effectByArm":[{"arm":"AK160 0.58 mg Step 1-2","deltaMin":86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":20,"countries":["Japan"]},"refs":{"pmids":["27313184"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":102},"commonTop":["Injection site pain","Injection site bruising","Injection site swelling","Contusion","Injection site laceration"]}}